Search Results - are

1442 Results

Sort By:

EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic...

Published: 7/2/2025 | Inventor(s): Tracy Ruckwardt, Daniel Moss, Peter Krug, Masaru Kanekiyo

Keywords(s):

Category(s): Application, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Synergistic Interactions for Improved Cancer Treatment

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer. Description of Technology: Immunotherapy has emerged as a promising treatment...

Published: 6/27/2025 | Inventor(s): Barbara Felber, George Pavlakis, Sevasti Karaliota, Dimitrios Stellas

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Establishment and characterization of the A 1847 human ovarian carcinoma line

Summary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage. Description of Technology: Mutations,...

Published: 6/27/2025 | Inventor(s): Stuart Aaronson, Nelson Ellmore (Estate)

Keywords(s):

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials

Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking

This technology includes a gene-based magnetic resonance imaging (MRI) reporter platform that harnesses adeno-associated virus (AAV) delivery of the metal transporter Zip14 to create image contrast wherever the gene is expressed. By driving Zip14 from cell-specific promoters, investigators obtain robust, long-lasting signal changes on standard clinical...

Published: 6/18/2025 | Inventor(s): Harikrishna (Hari) Rallapalli, Alan Koretsky, Raymond (Ray) Fields

Keywords(s):

Category(s): Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Radiology, Collaboration Sought > Licensing

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 6/13/2025 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Oral Iron-Chelator Therapy for Treating Developmental Stuttering

This technology discloses the use of small-molecule iron chelators—drugs that bind and remove excess iron—for the oral treatment of developmental stuttering in children and adults. Mouse models carrying human stuttering mutations show both elevated striatal iron and impaired vocalization; daily low-dose deferiprone reverses these speech-like...

Published: 6/13/2025 | Inventor(s): Shahriar SheikhBahaei

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Collaboration Sought > Licensing

Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties

One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists...

Published: 6/13/2025 | Inventor(s): Khalida Shamim, Wenwei Huang, Wei Zheng, Catherine Chen, Xiuli Huang, Xin Hu, Xin Xu, Pranav Shah, Elias Padilha, Philip Sanderson, Amy Newman

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health

P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain

This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy...

Published: 6/11/2025 | Inventor(s): Young-Hwan Jung, Zhiwei Wen, Kenneth Jacobson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Neurology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)

It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory...

Published: 5/30/2025 | Inventor(s): Juan Marugan, Mark Henderson, Kenneth Wilson, Wenwei Huang, Wenjuan Ye, Noel Southall, Jiankang Jiang, Khalida Shamim, Bing Li, Alexander Agoulnik, Abhijeet Kapoor, Joshua Hutcheson, Ana Cabrera, Irina Agoulnik

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Pulmonology, TherapeuticArea > Dermatology, TherapeuticArea > Reproductive Health, TherapeuticArea > Geriatrics

Antibodies to TMC1 Protein for Hearing Loss

This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1...

Published: 5/19/2025 | Inventor(s): Andrew Griffith, Tomoko Makishima, Valentina Labay

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, ResearchProducts > Antibodies, Collaboration Sought > Licensing, Collaboration Sought > Materials Available

1 2 3 4 5 6 7 8 9 10 ...